CoChat
Sign Up
Cited by 90

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Targeting MCL-1 protein to treat cancer: opportunities and challenges

Tantawy, Shady I., Timofeeva, Natalia, Sarkar, Aloke, Gandhi, Varsha·2023·Frontiers in Oncology
DOI 10.3389/fonc.2023.1226289PMC PMC10436212
Open this paper in CoChat — free account

Abstract

Evading apoptosis has been linked to tumor development and chemoresistance. One mechanism for this evasion is the overexpression of prosurvival B-cell lymphoma-2 (BCL-2) family proteins, which gives cancer cells a survival advantage. Mcl-1, a member of the BCL-2 family, is among the most frequently amplified genes in cancer. Targeting myeloid cell leukemia-1 (MCL-1) protein is a successful strategy to induce apoptosis and overcome tumor resistance to chemotherapy and targeted therapy. Various strategies to inhibit the antiapoptotic activity of MCL-1 protein, including transcription, translation, and the degradation of MCL-1 protein, have been tested. Neutralizing MCL-1’s function by targeting its interactions with other proteins via BCL-2 interacting mediator (BIM)S 2A has been shown to be an equally effective approach. Encouraged by the design of venetoclax and its efficacy in chronic lymphocytic leukemia, scientists have developed other BCL-2 homology (BH3) mimetics—particularly MCL-1 inhibitors (MCL-1i)—that are currently in clinical trials for various cancers. While extensive reviews of MCL-1i are available, critical analyses focusing on the challenges of MCL-1i and their optimization are lacking. In this review, we discuss the current knowledge regarding clinically relevant MCL-1i and focus on predictive biomarkers of response, mechanisms of resistance, major issues associated with use of MCL-1i, and the future use of and maximization of the benefits from these agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2023.1226289

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Structure of myeloid cell leukemia-1 (MCL-1) protein. MCL-1 protein consists of 350 amino acids, highlighting several important post-translational modification sites. Two caspase cleavage sites (aspartic acid [Asp] 127 and 157), 5 lysine [Lys] residues (5, 40, 136, 194, and 196) for ubiquitination, and 6 phosphorylation sites (serine [Ser] 64, threonine [Thr] 92, Ser 121, 155, and 159, and Thr 163) are indicated. The N-terminus of the protein is largely unstructured and includes 4 proline, glutamate, serine, and threonine (PEST) regions (2 major and 2 minor, labeled as “PEST” and “pest,” respectively). Four BCL-2 homology (BH) domains (BH1-BH4) are located near the C-terminus, which also contains the transmembrane (TM) domain necessary for mitochondrial localization.
Figure 1 Structure of myeloid cell leukemia-1 (MCL-1) protein. MCL-1 protein consists of 350 amino acids, highlighting several important post-translational modification sites. Two caspase cleavage sites (aspartic acid [Asp] 127 and 157), 5 lysine [Lys] residues (5, 40, 136, 194, and 196) for ubiquitination, and 6 phosphorylation sites (serine [Ser] 64, threonine [Thr] 92, Ser 121, 155, and 159, and Thr 163) are indicated. The N-terminus of the protein is largely unstructured and includes 4 proline, glutamate, serine, and threonine (PEST) regions (2 major and 2 minor, labeled as “PEST” and “pest,” respectively). Four BCL-2 homology (BH) domains (BH1-BH4) are located near the C-terminus, which also contains the transmembrane (TM) domain necessary for mitochondrial localization.CC BY · PubMed Central
Figure 2 Targeting myeloid cell leukemia-1 (MCL-1) protein. MCL-1 protein can be targeted either directly, by disrupting MCL-1 interaction with proapoptotic proteins (#3), or indirectly by targeting MCL-1 protein at stages of transcription(#1), translation(#2) or degradation(#4). Cyclin-dependent kinase (CDK)7/9 inhibitors or microRNA can block the transcription of MCL-1 messenger RNA (mRNA). SF3B1 inhibitors can generate a proapoptotic MCL-1S isoform by switching on alternative splicing. Once transcribed, MCL-1 mRNA moves to the cytoplasm for translation into MCL-1 protein (depicted in green). This translation process can be prevented with phosphatidylinositol-3 kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors or epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibitors. After translation, MCL-1 protein binds and deactivates the BAK/BAX complex (depicted in red/pink) in the outer mitochondrial membrane. This binding can be disrupted with direct MCL-1 inhibitors), leading to BAX/BAK dissociation and apoptosis. Additionally, the proteasomal degradation of MCL-1 can be enhanced using glycogen synthase kinase 3β (GSK3β) stimulants, extracellular signal-regulated kinase (ERK) inhibitors, the proteolysis-targeting chimera (PROTAC), or deubiquitinating enzymes (DUB) inhibitors (e.g., WP1130), thereby increasing MCL-1 polyubiquitination and subsequent degradation. CREB, cAMP response element-binding protein; GMCSF, Granulocyte-macrophage colony-stimulating factor; HIF-1α, Hypoxia-inducible factor 1-alpha; IL, interleukin; Ser, serine; STAT, signal transducer and activator of transcription; Thr, threonine.
Figure 2 Targeting myeloid cell leukemia-1 (MCL-1) protein. MCL-1 protein can be targeted either directly, by disrupting MCL-1 interaction with proapoptotic proteins (#3), or indirectly by targeting MCL-1 protein at stages of transcription(#1), translation(#2) or degradation(#4). Cyclin-dependent kinase (CDK)7/9 inhibitors or microRNA can block the transcription of MCL-1 messenger RNA (mRNA). SF3B1 inhibitors can generate a proapoptotic MCL-1S isoform by switching on alternative splicing. Once transcribed, MCL-1 mRNA moves to the cytoplasm for translation into MCL-1 protein (depicted in green). This translation process can be prevented with phosphatidylinositol-3 kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors or epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibitors. After translation, MCL-1 protein binds and deactivates the BAK/BAX complex (depicted in red/pink) in the outer mitochondrial membrane. This binding can be disrupted with direct MCL-1 inhibitors), leading to BAX/BAK dissociation and apoptosis. Additionally, the proteasomal degradation of MCL-1 can be enhanced using glycogen synthase kinase 3β (GSK3β) stimulants, extracellular signal-regulated kinase (ERK) inhibitors, the proteolysis-targeting chimera (PROTAC), or deubiquitinating enzymes (DUB) inhibitors (e.g., WP1130), thereby increasing MCL-1 polyubiquitination and subsequent degradation. CREB, cAMP response element-binding protein; GMCSF, Granulocyte-macrophage colony-stimulating factor; HIF-1α, Hypoxia-inducible factor 1-alpha; IL, interleukin; Ser, serine; STAT, signal transducer and activator of transcription; Thr, threonine.CC BY · PubMed Central
Figure 3 Mechanisms of myeloid cell leukemia-1 (MCL-1) protein upregulation by MCL-1 inhibitors. MCL-1i bind to the BCL-2 homology 3 (BH3) domain of MCL-1 and directly induce a conformation change/a state of MCL-1 that favors deubiquitination by deubiquitinating enzymes (DUBs [e.g., USP9x] rather than ubiquitination. This deubiquitination is further enhanced by Noxa disruption and rapid degradation, leading to enhanced DUBs activity on the MCL-1 protein. Additionally, the binding of MCL-1i transiently decreases the expression of the E3 ligase Mule and increases MEK/ERK-mediated threonine (Thr)163 phosphorylation of MCL-1, thus further contributing to the observed protein stability. Despite this upregulation of MCL-1 protein, MCL-1i disrupted the MCL-1–BAK/BAX interaction to induce apoptosis. The exact mechanism for MCL-1 upregulation was not studied using S63415, however, it is predicted to be the same owing to similar structure and function. Figure is adapted from Tantawy, et al, Clinical Cancer Research).
Figure 3 Mechanisms of myeloid cell leukemia-1 (MCL-1) protein upregulation by MCL-1 inhibitors. MCL-1i bind to the BCL-2 homology 3 (BH3) domain of MCL-1 and directly induce a conformation change/a state of MCL-1 that favors deubiquitination by deubiquitinating enzymes (DUBs [e.g., USP9x] rather than ubiquitination. This deubiquitination is further enhanced by Noxa disruption and rapid degradation, leading to enhanced DUBs activity on the MCL-1 protein. Additionally, the binding of MCL-1i transiently decreases the expression of the E3 ligase Mule and increases MEK/ERK-mediated threonine (Thr)163 phosphorylation of MCL-1, thus further contributing to the observed protein stability. Despite this upregulation of MCL-1 protein, MCL-1i disrupted the MCL-1–BAK/BAX interaction to induce apoptosis. The exact mechanism for MCL-1 upregulation was not studied using S63415, however, it is predicted to be the same owing to similar structure and function. Figure is adapted from Tantawy, et al, Clinical Cancer Research).CC BY · PubMed Central
Figure 4 The rationale for combination therapy using MCL-1 inhibitors. Myeloid cell leukemia-1 (MCL-1), B-cell lymphoma (BCL)-2 extra large (BCL-xL), and BCL-2 prosurvival proteins cooperate to bind and inactivate BAX, BAK complex, and other proapoptotic BCL-2 homology (BH)3-only proteins (Noxa, BIM, PUMA, BID, and BAD). When one of these prosurvival proteins loses its function (e.g., from MCL-1 inhibition by MCL-1i), the other proteins (BCL-2 and BCL-xL) may at least partially compensate for this loss. Thus, combination therapy using MCL-1i with a BCL-2 inhibitor (e.g., venetoclax) or BCL-2/BCL-xL inhibitor (e.g., navitoclax) appears promising and has been shown to be effective. Another way to enhance the activity of MCL-1i is to increase the expression of BH3-only proteins. Trametinib can upregulate BIM, which can then bind to MCL-1, thus increasing dependency on MCL-1 protein and subsequently increasing sensitivity to MCL-1i. BIM can also bind to BCL-2 or BCL-xL, indirectly inactivating them. Carfilzomib can upregulate Noxa, which is a BH3-only sensitizer protein that binds to MCL-1, leading to more BH3-only activator proteins (BIM, PUMA, and BID) becoming available to bind to BAX/BAK and activate downstream apoptosis. Chemotherapy induces DNA damage with subsequent activation of TP53 and induction of BAX and Noxa. In addition, various chemotherapeutic agents can downregulate MCL-1. MCL-1i can synergize with chemotherapy by inducing more DNA damage, possibly affecting DNA repair, and neutralizing MCL-1. Effect of the clinically relevant MCL-1i (S63845, AMG-176 and AZD5991) on DNA repair mechanisms needs to be further explored.
Figure 4 The rationale for combination therapy using MCL-1 inhibitors. Myeloid cell leukemia-1 (MCL-1), B-cell lymphoma (BCL)-2 extra large (BCL-xL), and BCL-2 prosurvival proteins cooperate to bind and inactivate BAX, BAK complex, and other proapoptotic BCL-2 homology (BH)3-only proteins (Noxa, BIM, PUMA, BID, and BAD). When one of these prosurvival proteins loses its function (e.g., from MCL-1 inhibition by MCL-1i), the other proteins (BCL-2 and BCL-xL) may at least partially compensate for this loss. Thus, combination therapy using MCL-1i with a BCL-2 inhibitor (e.g., venetoclax) or BCL-2/BCL-xL inhibitor (e.g., navitoclax) appears promising and has been shown to be effective. Another way to enhance the activity of MCL-1i is to increase the expression of BH3-only proteins. Trametinib can upregulate BIM, which can then bind to MCL-1, thus increasing dependency on MCL-1 protein and subsequently increasing sensitivity to MCL-1i. BIM can also bind to BCL-2 or BCL-xL, indirectly inactivating them. Carfilzomib can upregulate Noxa, which is a BH3-only sensitizer protein that binds to MCL-1, leading to more BH3-only activator proteins (BIM, PUMA, and BID) becoming available to bind to BAX/BAK and activate downstream apoptosis. Chemotherapy induces DNA damage with subsequent activation of TP53 and induction of BAX and Noxa. In addition, various chemotherapeutic agents can downregulate MCL-1. MCL-1i can synergize with chemotherapy by inducing more DNA damage, possibly affecting DNA repair, and neutralizing MCL-1. Effect of the clinically relevant MCL-1i (S63845, AMG-176 and AZD5991) on DNA repair mechanisms needs to be further explored.CC BY · PubMed Central
Figure 5 Effect of myeloid cell leukemia-1 (MCL-1) deletion or MCL-1 inhibitors on the heart. (A) Mcl-1 knockout in a mouse model led to dilated cardiomyopathy with thin ventricle walls and atrial thrombus, features of impaired cardiac hemodynamics. Ultrastructure changes in the mitochondria, myocyte degeneration, fibrosis, inflammation, and necrosis were observed. Mitochondrial dysfunction and impaired autophagy may have contributed to the observed toxicity. (B) Treating hiPSC-CMs with S68345 induced dynamin-related protein 1 (DRP-1–dependent mitochondrial dysfunction, cytoskeleton disruption, and impaired/irregular beating of the cardiomyocytes. The potential role of Noxa and Mule downregulation on cardiotoxicity needs to be further explored. ATP, adenosine triphosphate; OCR, oxygen consumption rate; OMM, outer mitochondrial membrane.
Figure 5 Effect of myeloid cell leukemia-1 (MCL-1) deletion or MCL-1 inhibitors on the heart. (A) Mcl-1 knockout in a mouse model led to dilated cardiomyopathy with thin ventricle walls and atrial thrombus, features of impaired cardiac hemodynamics. Ultrastructure changes in the mitochondria, myocyte degeneration, fibrosis, inflammation, and necrosis were observed. Mitochondrial dysfunction and impaired autophagy may have contributed to the observed toxicity. (B) Treating hiPSC-CMs with S68345 induced dynamin-related protein 1 (DRP-1–dependent mitochondrial dysfunction, cytoskeleton disruption, and impaired/irregular beating of the cardiomyocytes. The potential role of Noxa and Mule downregulation on cardiotoxicity needs to be further explored. ATP, adenosine triphosphate; OCR, oxygen consumption rate; OMM, outer mitochondrial membrane.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 193

  1. Kerr, 1972, Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics, Br J Cancer, 26, 10.1038/bjc.1972.33 · DOI
  2. Beroukhim, 2010, The landscape of somatic copy-number alteration across human cancers, Nature, 463, 899, 10.1038/nature08822 · DOI · Paper page
  3. Campbell, 2018, MCL-1 is a prognostic indicator and drug target in breast cancer, Cell Death Dis, 9, 1, 10.1038/s41419-017-0035-2 · DOI
  4. Golstein, 1998, Cell death in us and others, Am Assoc Adv Sci, 10.1126/science.281.5381.1283 · DOI
  5. Kluck, 1997, The release of cytochrome c from mitochondria: a primary site for bcl-2 regulation of apoptosis, Science, 275, 10.1126/science.275.5303.1132 · DOI
  6. Zou, 1997, Apaf-1, a human protein homologous to c. elegans CED-4, participates in cytochrome c–dependent activation of caspase-3, Cell, 90, 10.1016/S0092-8674(00)80501-2 · DOI
  7. Verhagen, 2000, Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins, cell, 102, 43, 10.1016/S0092-8674(00)00009-X · DOI · Paper page
  8. Du, 2000, Smac, a mitochondrial protein that promotes cytochrome c–dependent caspase activation by eliminating IAP inhibition, Cell, 102, 33, 10.1016/S0092-8674(00)00008-8 · DOI · Paper page
  9. Strasser, 2005, The role of BH3-only proteins in the immune system, Nat Rev Immunol, 5, 189, 10.1038/nri1568 · DOI
  10. Chao, 1998, BCL-2 family: regulators of cell death, Annu Rev Immunol, 16, 395, 10.1146/annurev.immunol.16.1.395 · DOI
  11. Akgul, 2000, In vivo localisation and stability of human mcl-1 using green fluorescent protein (GFP) fusion proteins, FEBS Lett, 478, 10.1016/S0014-5793(00)01809-3 · DOI
  12. Carrington, 2017, Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo, Cell Death Differ, 24, 10.1038/cdd.2017.30 · DOI
  13. Long, 2015, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, Lancet, 386, 10.1016/S0140-6736(15)60898-4 · DOI
  14. Kozopas, 1993, MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2, Proc Natl Acad Sci, 90, 10.1073/pnas.90.8.3516 · DOI
  15. Slomp, 2018, Role and regulation of pro-survival BCL-2 proteins in multiple myeloma, Front Oncol, 8, 10.3389/fonc.2018.00533 · DOI
  16. Shah, 2018, Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients, Leukemia, 32, 10.1038/leu.2017.179 · DOI
  17. Yin, 2016, Copy-number variation of MCL1 predicts overall survival of non-small-cell lung cancer in a southern Chinese population, Cancer Med, 5, 10.1002/cam4.774 · DOI
  18. Kim, 2009, MCL-1ES, a novel variant of MCL-1, associates with MCL-1L and induces mitochondrial cell death, FEBS Lett, 583, 10.1016/j.febslet.2009.08.006 · DOI
  19. Bae, 2000, MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain, J Biol Chem, 275, 10.1074/jbc.M909826199 · DOI
  20. Bingle, 2000, Exon skipping in mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death, J Biol Chem, 275, 10.1074/jbc.M909572199 · DOI
  21. Aird, 2019, Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators, Nat Commun, 10, 1, 10.1038/s41467-018-08150-5 · DOI
  22. Laetsch, 2014, Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma, Cell Death Dis, 5, 10.1038/cddis.2014.40 · DOI
  23. Yang, 1996, MCL-1, a member of the BCL-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation, J Cell Physiol, 166, 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R · DOI
  24. Michels, 2005, Mcl-1, Int J Biochem Cell Biol, 37, 10.1016/j.biocel.2004.04.007 · DOI
  25. Lutz, 2000, Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and bcl-2-related proteins, 10.1042/bst0280051 · DOI
  26. Yap, 2017, Expanding the cancer arsenal with targeted therapies: disarmament of the antiapoptotic bcl-2 proteins by small molecules: miniperspective, J Med Chem, 60, 10.1021/acs.jmedchem.5b01888 · DOI
  27. Craig, 2002, MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis, Leukemia, 16, 10.1038/sj.leu.2402416 · DOI
  28. Thomas, 2010, Mcl-1; the molecular regulation of protein function, FEBS Lett, 584, 10.1016/j.febslet.2010.05.061 · DOI
  29. Gores, 2012, Selectively targeting mcl-1 for the treatment of acute myelogenous leukemia and solid tumors, Genes Dev, 26, 10.1101/gad.186189.111 · DOI
  30. Mojsa, 2014, Mcl-1 ubiquitination: unique regulation of an essential survival protein, Cells, 3, 10.3390/cells3020418 · DOI
  31. Jourdan, 2000, Regulation of bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1, Cell Death Differ, 7, 10.1038/sj.cdd.4400758 · DOI
  32. Jiang, 2008, Up-regulation of mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress, Cancer Res, 68, 10.1158/0008-5472.CAN-08-0349 · DOI
  33. Piret, 2005, Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis, J Biol Chem, 280, 10.1074/jbc.M411858200 · DOI
  34. Mott, 2007, Mir-29 regulates mcl-1 protein expression and apoptosis, Oncogene, 26, 10.1038/sj.onc.1210436 · DOI
  35. Herrant, 2004, Cleavage of mcl-1 by caspases impaired its ability to counteract bim-induced apoptosis, Oncogene, 23, 10.1038/sj.onc.1208069 · DOI
  36. Song, 2016, Deactivation of mcl-1 by dual-function small-molecule inhibitors targeting the bcl-2 homology 3 domain and facilitating mcl-1 ubiquitination, Angewandte Chemie Int Edition, 55, 10.1002/anie.201606543 · DOI
  37. Czabotar, 2007, Structural insights into the degradation of mcl-1 induced by BH3 domains, Proc Natl Acad Sci, 104, 10.1073/pnas.0701297104 · DOI
  38. Ding, 2007, Degradation of mcl-1 by β-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization, Mol Cell Biol, 27, 10.1128/MCB.00620-06 · DOI
  39. Yang, 1995, The intracellular distribution and pattern of expression of mcl-1 overlap with, but are not identical to, those of bcl-2, J Cell Biol, 128, 10.1083/jcb.128.6.1173 · DOI
  40. Chen, 2005, Differential targeting of prosurvival bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function, Mol Cell, 17, 393, 10.1016/j.molcel.2004.12.030 · DOI · Paper page
  41. Benard, 2009, Mitochondrial fusion and division: regulation and role in cell viability, 10.1016/j.semcdb.2008.12.012 · DOI
  42. Escudero, 2018, Dynamic regulation of long-chain fatty acid oxidation by a noncanonical interaction between the MCL-1 BH3 helix and VLCAD, Mol Cell, 69, 729, 10.1016/j.molcel.2018.02.005 · DOI
  43. Perciavalle, 2012, Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration, Nat Cell Biol, 14, 10.1038/ncb2488 · DOI
  44. Hollville, 2014, Bcl-2 family proteins participate in mitochondrial quality control by regulating Parkin/PINK1-dependent mitophagy, Mol Cell, 55, 10.1016/j.molcel.2014.06.001 · DOI
  45. Cen, 2021, Targeting MCL1 to induce mitophagy is a potential therapeutic strategy for Alzheimer disease, Autophagy, 17, 10.1080/15548627.2020.1860542 · DOI
  46. Cen, 2020, Pharmacological targeting of MCL-1 promotes mitophagy and improves disease pathologies in an alzheimer’s disease mouse model, Nat Commun, 11, 5731, 10.1038/s41467-020-19547-6 · DOI
  47. Demelash, 2015, Structure-function analysis of the mcl-1 protein identifies a novel senescence-regulating domain, J Biol Chem, 290, 10.1074/jbc.M115.663898 · DOI
  48. Mattoo, 2017, MCL-1 depletion impairs DNA double-strand break repair and reinitiation of stalled DNA replication forks, Mol Cell Biol, 37, 10.1128/MCB.00535-16 · DOI
  49. Perciavalle, 2013, Delving deeper: MCL-1's contributions to normal and cancer biology, Trends Cell Biol, 23, 10.1016/j.tcb.2012.08.011 · DOI
  50. Zhou, 2001, MCL1 transgenic mice exhibit a high incidence of b-cell lymphoma manifested as a spectrum of histologic subtypes, Blood J Am Soc Hematol, 97, 10.1182/blood.V97.12.3902 · DOI
  51. Aichberger, 2005, Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides, Blood, 105, 10.1182/blood-2004-02-0749 · DOI
  52. Breitenbuecher, 2009, A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML, Blood J Am Soc Hematol, 113, 10.1182/blood-2007-11-126664 · DOI
  53. Fleischer, 2006, Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma, Int J Oncol, 28, 25, 10.3892/ijo.28.1.25 · DOI
  54. Henson, 2006, Herceptin sensitizes ErbB2–overexpressing cells to apoptosis by reducing antiapoptotic mcl-1 expression, Clin Cancer Res, 12, 10.1158/1078-0432.CCR-05-0754 · DOI
  55. Le Gouill, 2004, VEGF induces mcl-1 up-regulation and protects multiple myeloma cells against apoptosis, Blood, 104, 10.1182/blood-2004-05-1760 · DOI
  56. Song, 2005, Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells, Cancer Biol Ther, 4, 10.4161/cbt.4.3.1496 · DOI
  57. Wuilleme-Toumi, 2005, Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival, Leukemia, 19, 10.1038/sj.leu.2403784 · DOI
  58. Michels, 2004, Mcl-1 is required for Akata6 b-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage, Oncogene, 23, 10.1038/sj.onc.1207648 · DOI
  59. Cho-Vega, 2004, MCL-1 expression in b-cell non-hodgkin’s lymphomas, Hum Pathol, 35, 10.1016/j.humpath.2004.04.018 · DOI
  60. Kuramoto, 2002, High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-hodgkin's lymphoma, Br J Haematol, 116, 10.1046/j.1365-2141.2002.03253.x · DOI
  61. Lv, 2015, Somatic mutations in myeloid cell leukemia−1 contribute to the pathogenesis of glioma by prolonging its half−life, Mol Med Rep, 12, 10.3892/mmr.2015.3493 · DOI
  62. Ramsey, 2018, A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia, Cancer Discov, 8, 10.1158/2159-8290.CD-18-0140 · DOI
  63. Van Delft, 2006, The BH3 mimetic ABT-737 targets selective bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if mcl-1 is neutralized, Cancer Cell, 10, 10.1016/j.ccr.2006.08.027 · DOI
  64. Merino, 2018, BH3-mimetic drugs: blazing the trail for new cancer medicines, Cancer Cell, 34, 10.1016/j.ccell.2018.11.004 · DOI
  65. Balko, 2014, Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets, Cancer Discov, 4, 10.1158/2159-8290.CD-13-0286 · DOI
  66. Wei, 2008, Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting mcl-1 gene in pancreatic carcinoma cell, Cancer Chemother Pharmacol, 62, 10.1007/s00280-008-0697-7 · DOI
  67. Wertz, 2011, Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7, Nature, 471, 10.1038/nature09779 · DOI
  68. Zhang, 2022, Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia, Signal Transduct Targeted Ther, 7, 51, 10.1038/s41392-021-00870-3 · DOI
  69. Bhatt, 2020, Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia, Cancer Cell, 38, 872, 10.1016/j.ccell.2020.10.010 · DOI
  70. Michels, 2014, MCL-1 dependency of cisplatin-resistant cancer cells, Biochem Pharmacol, 92, 55, 10.1016/j.bcp.2014.07.029 · DOI
  71. Osaki, 2016, Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas, Sci Rep, 6, 28953, 10.1038/srep28953 · DOI
  72. Ohtsu, 2022, Fibroblast growth factor receptor inhibitor erdafitinib promotes mcl-1 degradation and synergistically induces apoptosis with bcl-xL/Bcl-2 inhibitor in urothelial cancer cells, Biochem Biophys Res Commun, 628, 76, 10.1016/j.bbrc.2022.08.083 · DOI
  73. Inuzuka, 2011, SCF FBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction, Nature, 471, 10.1038/nature09732 · DOI
  74. Troiani, 2022, Single-cell transcriptomics identifies mcl-1 as a target for senolytic therapy in cancer, Nat Commun, 13, 2177, 10.1038/s41467-022-29824-1 · DOI
  75. Carter, 2022, Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition, Haematologica, 107, 58, 10.3324/haematol.2020.260331 · DOI
  76. Huang, 2022, PIK-75 overcomes venetoclax resistance via blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma, Am J Cancer Res, 12, 1102
  77. Chen, 2009, Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia, Blood J Am Soc Hematol, 113, 10.1182/blood-2008-12-190256 · DOI
  78. Kitada, 2000, Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in b-cell chronic lymphocytic leukemia, Blood J Am Soc Hematol, 96, 10.1182/blood.V96.2.393 · DOI
  79. Gandhi, 2014, Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous LeukemiaOmacetaxine: a protein translation inhibitor in CML, Clin Cancer Res, 20, 10.1158/1078-0432.CCR-13-1283 · DOI · Paper page
  80. Liu, 2012, Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors, J Med Chem, 55, 10.1021/jm3011542 · DOI
  81. Abulwerdi, 2014, A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo, Mol Cancer Ther, 13, 10.1158/1535-7163.MCT-12-0767 · DOI
  82. Lee, 2015, MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large b cell lymphoma, Oncotarget, 6, 35202, 10.18632/oncotarget.6051 · DOI
  83. Rahmani, 2005, Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of mcl-1 through inhibition of translation, J Biol Chem, 280, 10.1074/jbc.M506551200 · DOI
  84. Kang, 2017, Degradation of mcl-1 through GSK-3β activation regulates apoptosis induced by bufalin in non-small cell lung cancer H1975 cells, Cell Physiol Biochem, 41, 10.1159/000475438 · DOI
  85. Nifoussi, 2012, Thr 163 phosphorylation causes mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer, PloS One, 7, 10.1371/journal.pone.0047060 · DOI
  86. Thrane, 2015, A kinase inhibitor screen identifies mcl-1 and aurora kinase a as novel treatment targets in antiestrogen-resistant breast cancer cells, Oncogene, 34, 10.1038/onc.2014.351 · DOI
  87. Lee, 2016, Allosteric inhibition of antiapoptotic MCL-1, Nat Struct Mol Biol, 23, 10.1038/nsmb.3223 · DOI · Paper page
  88. Lee, 2008, A novel BH3 ligand that selectively targets mcl-1 reveals that apoptosis can proceed without mcl-1 degradation, J Cell Biol, 180, 10.1083/jcb.200708096 · DOI
  89. Harvey, 2018, Crystal structures of anti-apoptotic BFL-1 and its complex with a covalent stapled peptide inhibitor, Structure, 26, 153, 10.1016/j.str.2017.11.016 · DOI
  90. Winter, 2012, Biophysical and computational fragment-based approaches to targeting protein–protein interactions: applications in structure-guided drug discovery, Q Rev Biophys, 45, 383, 10.1017/S0033583512000108 · DOI
  91. Rehman, 2023, Computational approaches for the design of modulators targeting protein-protein interactions, Expert Opin Drug Discovery, 10.1080/17460441.2023.2171396 · DOI
  92. Kitada, 2003, Discovery, characterization, and structure– activity relationships studies of proapoptotic polyphenols targeting b-cell lymphocyte/leukemia-2 proteins, J Med Chem, 46, 10.1021/jm030190z · DOI
  93. Arnold, 2008, Preclinical studies of apogossypolone: a new nonpeptidic pan small-molecule inhibitor of bcl-2, bcl-X l and mcl-1 proteins in follicular small cleaved cell lymphoma model, Mol Cancer, 7, 20, 10.1186/1476-4598-7-20 · DOI
  94. Tzung, 2001, Antimycin a mimics a cell-death-inducing bcl-2 homology domain 3, Nat Cell Biol, 3, 10.1038/35055095 · DOI · Paper page
  95. Acoca, 2011, Molecular dynamics study of small molecule inhibitors of the bcl-2 family, Proteins: Struct Function Bioinf, 79, 10.1002/prot.23083 · DOI
  96. Mohammad, 2007, Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both bcl-2 and mcl-1, Clin Cancer Res, 13, 10.1158/1078-0432.CCR-06-1574 · DOI
  97. Villalobos-Ortiz, 2020, BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics, Cell Death Differ, 27, 999, 10.1038/s41418-019-0391-9 · DOI
  98. Wan, 2018, Small-molecule mcl-1 inhibitors: emerging anti-tumor agents, Eur J Med Chem, 146, 10.1016/j.ejmech.2018.01.076 · DOI
  99. Belmar, 2015, Small molecule mcl-1 inhibitors for the treatment of cancer, Pharmacol Ther, 145, 76, 10.1016/j.pharmthera.2014.08.003 · DOI
  100. Day, 2005, Solution structure of prosurvival mcl-1 and characterization of its binding by proapoptotic BH3-only ligands, J Biol Chem, 280, 10.1074/jbc.M411434200 · DOI
  101. Arkin, 2014, Small-molecule inhibitors of protein-protein interactions: progressing toward the reality, Chem Biol, 21, 10.1016/j.chembiol.2014.09.001 · DOI · Paper page
  102. Marimuthu, 2020, Disruption of conserved polar interactions causes a sequential release of bim mutants from the canonical binding groove of Mcl1, Int J Biol Macromol, 158, 10.1016/j.ijbiomac.2020.04.243 · DOI
  103. Shaw, 2018, Optimization of potent and selective tricyclic indole diazepinone myeloid cell leukemia-1 inhibitors using structure-based design, J Med Chem, 61, 10.1021/acs.jmedchem.7b01155 · DOI
  104. Dutta, 2010, Determinants of BH3 binding specificity for mcl-1 versus bcl-xL, J Mol Biol, 398, 10.1016/j.jmb.2010.03.058 · DOI
  105. Stewart, 2010, The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer, Nat Chem Biol, 6, 595, 10.1038/nchembio.391 · DOI · Paper page
  106. Negi, 2021, Development of mcl-1 inhibitors for cancer therapy, Eur J Med Chem, 210, 113038, 10.1016/j.ejmech.2020.113038 · DOI
  107. Caenepeel, 2018, AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies, Cancer Discov, 8, 10.1158/2159-8290.CD-18-0387 · DOI · Paper page
  108. Tron, 2018, Discovery of mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia, Nat Commun, 9, 1, 10.1038/s41467-018-07551-w · DOI
  109. Caenepeel, 2020, Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor, Cancer Res, 80, 10.1158/1538-7445.AM2020-6218 · DOI
  110. Leverson, 2015, Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax), Cell Death Dis, 6, 10.1038/cddis.2014.561 · DOI · Paper page
  111. Xiao, 2015, MCL-1 is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor, Mol Cancer Ther, 14, 10.1158/1535-7163.MCT-14-0928 · DOI
  112. Wang, 2019, A−1210477, a selective MCL−1 inhibitor, overcomes ABT−737 resistance in AML, Oncol Lett, 18, 10.3892/ol.2019.10891 · DOI
  113. Meister, 2019, Concomitant targeting of hedgehog signaling and MCL-1 synergistically induces cell death in hedgehog-driven cancer cells, Cancer Lett, 465, 1, 10.1016/j.canlet.2019.08.012 · DOI
  114. Fiskus, 2019, Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells, Blood Cancer J, 9, 1, 10.1038/s41408-018-0165-5 · DOI
  115. Ow, 2019, Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1, Oncotarget, 10, 494, 10.18632/oncotarget.26563 · DOI
  116. Widden, 2020, MCL1 binds and negatively regulates the transcriptional function of tumor suppressor p73, Cell Death Dis, 11, 946, 10.1038/s41419-020-03068-7 · DOI
  117. Pelz, 2016, Discovery of 2-indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods, J Med Chem, 59, 10.1021/acs.jmedchem.5b01660 · DOI
  118. Williams, 2019, Therapeutic inhibition of mcl-1 blocks cell survival in estrogen receptor-positive breast cancers, Oncotarget, 10, 5389, 10.18632/oncotarget.27070 · DOI
  119. Song, 2020, Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer, Theranostics, 10, 8098, 10.7150/thno.45363 · DOI
  120. Koch, 2019, Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas, Blood J Am Soc Hematol, 133, 10.1182/blood-2018-07-865527 · DOI
  121. Sale, 2019, Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors, Nat Commun, 10, 1, 10.1038/s41467-019-12409-w · DOI
  122. Timofeeva, 2023, Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia, Front Oncol, 13, 10.3389/fonc.2023.1161254 · DOI
  123. Yi, 2020, AMG-176, an mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia, Clin Cancer Res, 26, 10.1158/1078-0432.CCR-19-1397 · DOI
  124. Sulkshane, 2022, Myeloid cell leukemia-1: a formidable barrier to anticancer therapeutics and the quest of targeting it, Explor Targeted Anti-tumor Ther, 3, 278, 10.37349/etat.2022.00083 · DOI
  125. Roberts, 2021, BCL2 and MCL1 inhibitors for hematologic malignancies, Blood J Am Soc Hematol, 138, 10.1182/blood.2020006785 · DOI
  126. Li, 2019, The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells, Leukemia, 33, 10.1038/s41375-018-0201-2 · DOI
  127. Manzano, 2018, Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma, Nat Commun, 9, 1, 10.1038/s41467-018-05506-9 · DOI
  128. Chen, 2019, Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells, Leukemia Lymphoma, 10.1080/10428194.2019.1622098 · DOI
  129. Moujalled, 2019, Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia, Leukemia, 33, 10.1038/s41375-018-0261-3 · DOI
  130. Merino, 2017, Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer, Sci Trans Med, 9, 10.1126/scitranslmed.aam7049 · DOI
  131. Brennan, 2018, Humanized mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use, Blood J Am Soc Hematol, 132, 10.1182/blood-2018-06-859405 · DOI
  132. Bhagwat, 2021, Preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1, Cancer Res, 81, 10.1158/1538-7445.AM2021-983 · DOI
  133. Tantawy, 2023, Mechanisms of MCL-1 protein stability induced by MCL-1 antagonists in b-cell malignancies, Clin Cancer Res, 29, 10.1158/1078-0432.CCR-22-2088 · DOI
  134. Haschka, 2020, MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment, Cell Death Differ, 27, 10.1038/s41418-020-0503-6 · DOI
  135. Tantawy, 2023, Decoding the mechanism behind MCL-1 inhibitors: a pathway to understanding MCL-1 protein stability, Oncotarget, 14, 653, 10.18632/oncotarget.28440 · DOI
  136. Friberg, 2013, Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design, J Med Chem, 56, 15, 10.1021/jm301448p · DOI
  137. Hird, 2019, Recent advances in the development of mcl-1 inhibitors for cancer therapy, Pharmacol Ther, 198, 59, 10.1016/j.pharmthera.2019.02.007 · DOI
  138. Daressy, 2022, NA1–115—7, from zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes, Biomed Pharmacother, 154, 113546, 10.1016/j.biopha.2022.113546 · DOI
  139. Valentini, 2022, Targeting the anti-apoptotic bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small molecules, Theranostics, 12, 2427, 10.7150/thno.64233 · DOI
  140. Drennen, 2022, Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads, RSC Med Chem, 13, 10.1039/D2MD00095D · DOI
  141. Uthale, 2022, Identification of bicyclic compounds that act as dual inhibitors of bcl-2 and mcl-1, Mol Diversity, 1, 10.1007/s11030-022-10494-6 · DOI
  142. Hikita, 2009, Mcl-1 and bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver, Hepatology, 50, 10.1002/hep.23126 · DOI
  143. Roberts, 2012, Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease, J Clin Oncol, 30, 488, 10.1200/JCO.2011.34.7898 · DOI
  144. Kipps, 2015, A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated b-cell chronic lymphocytic leukemia, Leukemia Lymphoma, 56, 10.3109/10428194.2015.1030638 · DOI
  145. Fletcher, 2019, MCL-1 inhibitors–where are we now (2019), Expert Opin Ther Patents, 29, 10.1080/13543776.2019.1672661 · DOI
  146. Wei, 2012, Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency, Cancer Cell, 21, 10.1016/j.ccr.2012.02.028 · DOI
  147. Letai, 2005, The molecular basis for BCL-2 oncogene addiction in CLL, Am Soc Hematol, 10.1182/blood.V106.11.5008.5008 · DOI
  148. Liu, 2022, Cotargeting of bcl-2 and mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance, Exp Hematol, 105, 39, 10.1016/j.exphem.2021.10.006 · DOI
  149. Thijssen, 2021, Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias, Blood J Am Soc Hematol, 137, 10.1182/blood.2020010167 · DOI
  150. Nangia, 2018, Exploiting MCL1 dependency with combination MEK+ MCL1 inhibitors leads to induction of apoptosis and tumor regression in KRAS-mutant non–small cell lung cancer, Cancer Discov, 8, 10.1158/2159-8290.CD-18-0277 · DOI · Paper page
  151. Touzeau, 2018, Targeting bcl-2 for the treatment of multiple myeloma, Leukemia, 32, 10.1038/s41375-018-0223-9 · DOI
  152. Ponder, 2016, Dual inhibition of mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma, Cancer Biol Ther, 17, 10.1080/15384047.2016.1192086 · DOI
  153. Nguyen, 2018, Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms, BMC Cancer, 18, 1, 10.1186/s12885-018-5018-x · DOI
  154. Happo, 2010, Maximal killing of lymphoma cells by DNA damage–inducing therapy requires not only the p53 targets puma and noxa, but also bim, Blood J Am Soc Hematol, 116, 10.1182/blood-2010-04-280818 · DOI
  155. Wang, 2023, Synergistic activity and mechanism of cytarabine and MCL-1 inhibitor AZD5991 against acute myeloid leukemia, Neoplasma, 10.4149/neo_2023_221217N1185 · DOI
  156. Chen, 2018, Targeting mcl-1 enhances DNA replication stress sensitivity to cancer therapy, J Clin Invest, 128, 10.1158/1538-7445.AM2018-328 · DOI
  157. Ebrahimi, 2022, Synergistic apoptotic effect of mcl-1 inhibition and doxorubicin on b-cell precursor acute lymphoblastic leukemia cells, Mol Biol Rep, 49, 10.1007/s11033-021-07021-5 · DOI
  158. Seipel, 2019, Rationale for a combination therapy consisting of MCL1-and MEK-inhibitors in acute myeloid leukemia, Cancers, 11, 1779, 10.3390/cancers11111779 · DOI
  159. Winkler, 2022, Co-Targeting MCL-1 and ERK1/2 kinase induces mitochondrial apoptosis in rhabdomyosarcoma cells, Trans Oncol, 16, 101313, 10.1016/j.tranon.2021.101313 · DOI
  160. Rauh, 2023, ANJ810 is a highly selective novel MCL1 inhibitor with optimized in vivo clearance showing robust efficacy in preclinical solid and hematological tumor models, Cancer Res, 83, 10.1158/1538-7445.AM2023-506 · DOI
  161. Corcoran, 2013, Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models, Cancer Cell, 23, 10.1016/j.ccr.2012.11.007 · DOI · Paper page
  162. Gupta, 2017, Bone marrow microenvironment–derived signals induce mcl-1 dependence in multiple myeloma, Blood J Am Soc Hematol, 129, 10.1182/blood-2016-10-745059 · DOI · Paper page
  163. Pei, 2014, Circumvention of mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells, PloS One, 9, 10.1371/journal.pone.0089064 · DOI
  164. Balakrishnan, 2009, AT-101 induces apoptosis in CLL b cells and overcomes stromal cell–mediated mcl-1 induction and drug resistance, Blood J Am Soc Hematol, 113, 10.1182/blood-2008-02-138560 · DOI
  165. Dengler, 2020, Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma, Oncogene, 39, 10.1038/s41388-019-1122-x · DOI
  166. Wang, 2021, MCL-1 dependency as a novel vulnerability for aggressive b cell lymphomas, Blood Cancer J, 11, 14, 10.1038/s41408-020-00402-2 · DOI
  167. Liu, 2021, Pharmacologic targeting of mcl-1 induces mitochondrial dysfunction and apoptosis in b-cell lymphoma cells in a TP53-and BAX-dependent MannerMcl-1 inhibition in lymphoma, Clin Cancer Res, 27, 10.1158/1078-0432.CCR-21-0464 · DOI
  168. Sumarni, 2022, Sensitivity of cutaneous T-cell lymphoma cells to the mcl-1 inhibitor S63845 correlates with the lack of bcl-w expression, Int J Mol Sci, 23, 12471, 10.3390/ijms232012471 · DOI
  169. Bolomsky, 2021, Heterogeneous modulation of bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma, Blood Adv, 5, 10.1182/bloodadvances.2020003826 · DOI
  170. Tausch, 2019, Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia, Haematologica, 104, 10.3324/haematol.2019.222588 · DOI
  171. Chen, 2018, Myeloma patient-derived MCL1 point mutations can influence MCL1-inhibitor function, Blood, 132, 951, 10.1182/blood-2018-99-113444 · DOI
  172. Liu, 2022, C-myc plays a critical role in the antileukemic activity of the mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia, Apoptosis, 1, 10.1007/s10495-022-01756-7 · DOI
  173. Gomez-Bougie, 2018, BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment, Blood J Am Soc Hematol, 132, 10.1182/blood-2018-03-836718 · DOI
  174. Moyzis, 2017, MCL-1 regulates mitochondrial fission and mitophagy, Circulation, 136, 10.1161/res.119.suppl_1.375 · DOI
  175. Wang, 2013, Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction, Genes Dev, 27, 10.1101/gad.215855.113 · DOI
  176. Thomas, 2013, Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure, Genes Dev, 27, 10.1101/gad.215871.113 · DOI
  177. Kuznetsov, 2009, Heterogeneity of mitochondria and mitochondrial function within cells as another level of mitochondrial complexity, Int J Mol Sci, 10, 10.3390/ijms10041911 · DOI
  178. Rasmussen, 2020, MCL-1 inhibition by selective BH3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes, Iscience, 23, 101015, 10.1016/j.isci.2020.101015 · DOI
  179. Walsh, 2009, Modulation of calcium signalling by mitochondria, Biochim Biophys Acta (BBA)-Bioenergetics, 1787, 10.1016/j.bbabio.2009.01.007 · DOI
  180. Frederick, 2007, Moving mitochondria: establishing distribution of an essential organelle, Traffic, 8, 10.1111/j.1600-0854.2007.00644.x · DOI
  181. Cadenas, 2010, Mitochondrial reprogramming through cardiac oxygen sensors in ischaemic heart disease, Cardiovasc Res, 88, 10.1093/cvr/cvq256 · DOI
  182. Rosca, 2010, Mitochondria in heart failure, Cardiovasc Res, 88, 40, 10.1093/cvr/cvq240 · DOI
  183. Verdejo, 2012, Mitochondria, myocardial remodeling, and cardiovascular disease, Curr Hypertension Rep, 14, 10.1007/s11906-012-0305-4 · DOI
  184. Gu, 2016, Rapamycin inhibits cardiac hypertrophy by promoting autophagy via the MEK/ERK/Beclin-1 pathway, Front Physiol, 7, 10.3389/fphys.2016.00104 · DOI
  185. Xiao, 2019, The true colors of autophagy in doxorubicin−induced cardiotoxicity, Oncol Lett, 18, 10.3892/ol.2019.10576 · DOI
  186. Wang, 2018, Autophagy regulates apoptosis by targeting NOXA for degradation, Biochim Biophys Acta (BBA)-Mol Cell Res, 1865, 10.1016/j.bbamcr.2018.05.007 · DOI
  187. Dadson, 2017, The E3 ligase mule protects the heart against oxidative stress and mitochondrial dysfunction through myc-dependent inactivation of pgc-1α and Pink1, Sci Rep, 7, 1, 10.1038/srep41490 · DOI
  188. Senichkin, 2019, Molecular comprehension of mcl-1: from gene structure to cancer therapy, Trends Cell Biol, 29, 10.1016/j.tcb.2019.03.004 · DOI
  189. Guièze, 2019, Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies, Cancer Cell, 36, 369, 10.1016/j.ccell.2019.08.005 · DOI · Paper page
  190. Moore, 2007, Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737, J Clin Invest, 117, 10.1172/JCI28281 · DOI
  191. Cervantes-Gomez, 2015, Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic LeukemiaCombination of ABT-199 and ibrutinib for CLL, Clin Cancer Res, 21, 10.1158/1078-0432.CCR-14-2809 · DOI
  192. Jain, 2019, Ibrutinib and venetoclax for first-line treatment of CLL, New Engl J Med, 380, 10.1056/NEJMoa1900574 · DOI
  193. Tam, 2020, Ibrutinib plus venetoclax in patients with relapsed/refractory mantle cell lymphoma: results from the safety run-in period of the phase 3 sympatico study, Blood, 136, 39, 10.1182/blood-2020-134392 · DOI

Cited by

Sorted by citations

Metadata

Authors
Tantawy, S. I., Timofeeva, N., Sarkar, A., & Gandhi, V.
Venue
Frontiers in Oncology
Publisher
Frontiers Media SA
Published
2023-07-31
Volume
13
ISSN
2234-943X
DOI
10.3389/fonc.2023.1226289
PMC
PMC10436212
Cited by
90
References
9
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • CLL Global Research Foundation
  • University of Texas MD Anderson Cancer Center

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review